EAM Investors LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)

EAM Investors LLC purchased a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 53,026 shares of the company’s stock, valued at approximately $2,839,000.

Other large investors have also added to or reduced their stakes in the company. Barclays PLC increased its stake in shares of Janux Therapeutics by 51.7% during the fourth quarter. Barclays PLC now owns 263,970 shares of the company’s stock valued at $14,133,000 after buying an additional 89,909 shares during the period. Quinn Opportunity Partners LLC bought a new stake in Janux Therapeutics in the fourth quarter valued at $1,071,000. Kennedy Capital Management LLC boosted its holdings in Janux Therapeutics by 7.9% in the fourth quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company’s stock valued at $681,000 after acquiring an additional 928 shares in the last quarter. Legal & General Group Plc increased its position in Janux Therapeutics by 45.3% during the 4th quarter. Legal & General Group Plc now owns 34,540 shares of the company’s stock valued at $1,849,000 after purchasing an additional 10,776 shares during the period. Finally, Invesco Ltd. raised its holdings in Janux Therapeutics by 2,764.4% in the 4th quarter. Invesco Ltd. now owns 284,662 shares of the company’s stock worth $15,241,000 after purchasing an additional 274,724 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. Scotiabank reduced their target price on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 28th. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Wedbush reaffirmed an “outperform” rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $95.25.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock opened at $28.69 on Thursday. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of -24.52 and a beta of 3.27. Janux Therapeutics, Inc. has a 1 year low of $22.52 and a 1 year high of $71.71. The firm’s 50-day moving average is $30.96 and its 200 day moving average is $43.81.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Insider Activity

In related news, insider Andrew Hollman Meyer sold 3,334 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total value of $140,994.86. Following the sale, the insider now owns 82,139 shares in the company, valued at approximately $3,473,658.31. This trade represents a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. bought 110,206 shares of the business’s stock in a transaction on Friday, March 7th. The stock was bought at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the transaction, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. This trade represents a 1.10 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 29.40% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.